Company Filing History:
Years Active: 2013
Title: Innovations by Kyoung-Mi Juhn: Advancements in Cancer Treatment
Introduction: Kyoung-Mi Juhn, an inventive mind based in Seoul, South Korea, has made significant strides in the field of medical biotechnology. Notably, he has a patent that addresses the critical challenge of treating malignant tumors, emphasizing his role as a pioneer in cancer therapy.
Latest Patents: Kyoung-Mi Juhn holds a patent for a pharmaceutical composition aimed at treating malignant tumors. This composition includes a human p31 gene encoding protein, specifically represented by SEQ ID NO: 3 or 4, as a key component. This innovative treatment approach not only suppresses cancer cell growth but also induces apoptosis, effectively eliminating cancer cells through the overexpression of p31 in solid malignant tumor tissues. This breakthrough pharmaceutical composition is poised to play a vital role in gene therapy for cancer patients.
Career Highlights: Kyoung-Mi Juhn works at the Korea Institute of Radiological and Medical Sciences, where he contributes his expertise in advancing medical research and therapeutic solutions. His work has been recognized in various scientific circles, showcasing his commitment to improving cancer treatment methodologies.
Collaborations: Throughout his career, Kyoung-Mi Juhn has collaborated with esteemed colleagues such as Kee-Ho Lee and Sang-Hoon Kim. These collaborations reflect a joint effort in advancing cancer treatment and developing innovative pharmaceutical compositions.
Conclusion: Kyoung-Mi Juhn's contributions to the field of medical biotechnology, particularly in the area of cancer treatment, underscore his role as a significant inventor. With his innovative approach to gene therapy through the use of the human p31 gene, he continues to pave the way for future breakthroughs in oncology, offering hope to many affected by malignant tumors.